Nathan Connel: How Policy Changes Redefine Medical Care
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared a post on LinkedIn about a recent article by Glenn F. Pierce published in Haemophilia, adding:
“Global health policy doesn’t change easily, but when it does, it can redefine standards of care for millions.
This Haemophilia Journal commentary describes how coordinated advocacy by the World Federation of Hemophilia and the global bleeding disorders community led to major updates to the 2025 World Health Organization Essential Medicines List.
The stakes were high: the 2023 EML had effectively positioned cryoprecipitate as first-line therapy for hemophilia, a move that risked reversing decades of progress in safety and efficacy.
Following sustained global engagement across clinicians, patient organizations, and policymakers, the 2025 revisions achieved a critical course correction:
- Removal of cryoprecipitate for hemophilia/VWD indications
- Addition of recombinant FVIII and FIX to the core list
- Inclusion of emicizumab as a core essential medicine
- Elevation of plasma-derived factors to core status
- Elimination of outdated or higher-risk alternatives, such as prothrombin complex concentrates in place of FIX concentrates
Because many countries directly adopt the WHO EML, these changes will influence national policy, procurement, and access, particularly in low – and middle – income settings where treatment gaps remain profound.
Bottom line: Evidence-based advocacy, when globally coordinated, can realign policy with modern standards of care and materially improve outcomes for patients worldwide.”
Title: United Global Advocacy Drives Updates to World Health Organization Essential Medicines List
Authors: Glenn F. Pierce, Radek Kaczmarek, David Page, Alain Baumann, Albert Farrugia, Cesar Garrido, Maria Elisa Mancuso, Brian O’Mahony, Mark W. Skinner, Salome Mekhuzla
Read the Full Article on Haemophilia
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 1, 2026, 14:58Steve Cleveland: Tumor-Educated Platelets as a Platform for Early Cancer Detection
-
Apr 1, 2026, 14:53Hayley Emma Arron: Supporting Future Strategies for Venous Thrombosis in Spaceflight and Exploration
-
Apr 1, 2026, 14:44Chad Mineo: Platelet-Rich Plasma as an Adjunct to Rehabilitation in Grade 2 Hamstring Injuries
-
Apr 1, 2026, 14:41How Psychosocial Care Transforms Fear into Clarity and Stability – WFH
-
Apr 1, 2026, 14:23Ingo Ahrens: When Bleeding Poses a Greater Risk Than Ischemia
-
Apr 1, 2026, 13:48Anas Ibraheem: Apixaban Shows Superior Safety in Acute VTE While Matching Rivaroxaban Efficacy
-
Apr 1, 2026, 13:29Kevin Shortall: Life-Saving Blood Donation Amid Ireland’s Shortage
-
Apr 1, 2026, 13:12Kalyan Roy: Wrong Blood in Tube – A Small Error with Life-Threatening Consequences
-
Apr 1, 2026, 12:37Yves Bikorimana։ Normal MCV Doesn’t Always Mean Normal RBCs